Discover
ACRV
Acrivon Therapeutics, Inc. Common Stock
1.72
1 x 0.73
1 x 1.78
bid
ask
-
0.03
1.71%
09:32 AM
timesize
| Ytd | -28.63% | |
| 1y | 23.74% |
day range
1.20
52 week range
3.56
| Open | Prev Close | 1.75 | Low | High | Mkt Cap | 55.22M | |||
| Vol | 9.22K | Avg Vol | 558.53K | EPS | -2.00 | P/E | -0.87 | Forward P/E | -2.31 |
| Beta | 1.82 | Short Ratio | 15.38 | Inst. Own | 75.98% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 1.70 | 200-d Avg | 1.88 | 1yr Est | 21.11 |
| Income Statement | |||
| Operating Expenses | 19.90M | ||
| Research and Development Expense | 15.17M | ||
| Selling, General and Administrative Expense | 4.74M | ||
| Operating Income | -19.90M | ||
| Net Income | -19.04M | ||
| Net Income Common Stock | -19.04M | ||
| Net Income Common Stock (USD) | -19.04M | ||
| Consolidated Income | -19.04M | ||
| Earnings per Basic Share | -0.49 | ||
| Earnings per Basic Share (USD) | -0.49 | ||
| Earnings per Diluted Share | -0.49 | ||
| Earning Before Interest & Taxes (EBIT) | -19.04M | ||
| Earning Before Interest & Taxes (USD) | -19.04M | ||
| Weighted Average Shares | 38.72M | ||
| Weighted Average Shares Diluted | 38.72M | ||
| Balance Sheet | |||
| Cash and Equivalents | 34.26M | ||
| Cash and Equivalents (USD) | 34.26M | ||
| Investments | 63.67M | ||
| Investments Current | 63.67M | ||
| Current Assets | 99.22M | ||
| Property, Plant & Equipment Net | 6.91M | ||
| Total Assets | 107.83M | ||
| Debt Current | 1.15M | ||
| Total Debt | 2.42M | ||
| Current Liabilities | 11.05M | ||
| Debt Non-Current | 1.26M | ||
| Total Liabilities | 12.32M | ||
| Accumulated Retained Earnings (Deficit) | -293.92M | ||
| Accumulated Other Comprehensive Income | 4.00K | ||
| Shareholders Equity | 95.52M | ||
| Shareholders Equity (USD) | 95.52M | ||
| Assets Non-Current | 8.61M | ||
| Total Debt (USD) | 2.42M | ||
| Liabilities Non-Current | 1.26M | ||
| Trade and Non-Trade Payables | 1.16M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 656.00K | ||
| Net Cash Flow from Financing | -33.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -7.44M | ||
| Capital Expenditure | -14.00K | ||
| Net Cash Flow from Investing | 13.13M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 13.14M | ||
| Net Cash Flow from Operations | -20.54M | ||
| Share Based Compensation | 2.18M | ||